PSTV vs. NURO, TMDIF, VAPO, GCTK, VVOS, PYPD, UTRS, OSA, INBS, and AFIB
Should you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include NeuroMetrix (NURO), Titan Medical (TMDIF), Vapotherm (VAPO), GlucoTrack (GCTK), Vivos Therapeutics (VVOS), PolyPid (PYPD), Minerva Surgical (UTRS), ProSomnus (OSA), Intelligent Bio Solutions (INBS), and Acutus Medical (AFIB). These companies are all part of the "surgical & medical instruments" industry.
NeuroMetrix (NASDAQ:NURO) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
5.1% of NeuroMetrix shares are owned by institutional investors. Comparatively, 3.5% of Plus Therapeutics shares are owned by institutional investors. 7.5% of NeuroMetrix shares are owned by company insiders. Comparatively, 2.3% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NeuroMetrix has higher revenue and earnings than Plus Therapeutics. NeuroMetrix is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Plus Therapeutics has a consensus target price of $10.00, indicating a potential upside of 446.45%. Given NeuroMetrix's higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than NeuroMetrix.
NeuroMetrix has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
In the previous week, NeuroMetrix had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for NeuroMetrix and 0 mentions for Plus Therapeutics. NeuroMetrix's average media sentiment score of 1.37 beat Plus Therapeutics' score of 0.15 indicating that Plus Therapeutics is being referred to more favorably in the news media.
NeuroMetrix received 221 more outperform votes than Plus Therapeutics when rated by MarketBeat users. Likewise, 62.56% of users gave NeuroMetrix an outperform vote while only 60.58% of users gave Plus Therapeutics an outperform vote.
NeuroMetrix has a net margin of -110.64% compared to NeuroMetrix's net margin of -271.04%. Plus Therapeutics' return on equity of -31.31% beat NeuroMetrix's return on equity.
Summary
NeuroMetrix beats Plus Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Plus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Plus Therapeutics Competitors List
Related Companies and Tools